Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of “Moderate Buy” from Analysts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $13.30.

Several research analysts have recently issued reports on the stock. Citizens Jmp cut shares of Iovance Biotherapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, May 9th. The Goldman Sachs Group decreased their price objective on shares of Iovance Biotherapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, May 12th. Chardan Capital decreased their price objective on shares of Iovance Biotherapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Friday, May 9th. Mizuho decreased their price objective on shares of Iovance Biotherapeutics from $30.00 to $10.00 and set an “outperform” rating for the company in a report on Monday, May 12th. Finally, Robert W. Baird decreased their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, February 28th.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $1.75 on Friday. The firm has a 50 day simple moving average of $2.80 and a 200-day simple moving average of $5.15. The stock has a market capitalization of $585.05 million, a PE ratio of -1.18 and a beta of 1.06. Iovance Biotherapeutics has a 12-month low of $1.64 and a 12-month high of $12.51.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.11). The company had revenue of $49.32 million during the quarter, compared to the consensus estimate of $83.40 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The company’s revenue was up 6795.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.42) earnings per share. On average, analysts forecast that Iovance Biotherapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Iovance Biotherapeutics during the fourth quarter valued at approximately $515,000. Jennison Associates LLC purchased a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at approximately $493,000. Barclays PLC lifted its position in shares of Iovance Biotherapeutics by 118.8% in the 3rd quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock valued at $5,677,000 after acquiring an additional 328,284 shares in the last quarter. Banque Pictet & Cie SA lifted its position in shares of Iovance Biotherapeutics by 17.0% in the 4th quarter. Banque Pictet & Cie SA now owns 376,591 shares of the biotechnology company’s stock valued at $2,787,000 after acquiring an additional 54,832 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Iovance Biotherapeutics by 7.4% in the 4th quarter. Northern Trust Corp now owns 2,414,807 shares of the biotechnology company’s stock valued at $17,870,000 after acquiring an additional 166,231 shares in the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.